Pharmaceutical firm to invest £5m in Cramlington manufacturing facility

Watch more of our videos on Shots! 
and live on Freeview channel 276
Visit Shots! now
Manufacturing facilities in Northumberland will see £5m of investment, according to a drugs company’s latest accounts.

Pharmaron Manufacturing Services UK’s 2023 annual report, published earlier this month, confirmed that lass year bosses signed off on spending around £5m on upgrades to the company’s site at Windmill Industrial Estate in Cramlington.

The firm, a subsidiary of Chinese pharmaceutical company Pharmaron, acquired the site by taking over Aesica Pharmaceuticals in 2022.

Hide Ad
Hide Ad

The investment will be used for “modular configuration and upgrade of technical facilities” and, according to accounting documents, the company is “in the process of reviewing its plans” for the site.

Pharmaron has a manufacturing facility in Cramlington. (Photo by Google)Pharmaron has a manufacturing facility in Cramlington. (Photo by Google)
Pharmaron has a manufacturing facility in Cramlington. (Photo by Google)

The facility has “the financial support of its ultimate parent to continue with its development plans,” according to the document.

Read More
New report highlights strength of pharmaceutical sector in Northumberland

In his report, company director Stephen Lewinton said: “Pharmaron acquired the site at Cramlington for its large scale, active pharmaceutical ingredients manufacturing capability, and the strategic fit with the business growth and development plans for Pharmaron.

“The long-term strategic plan for the site is to increase operational flexibility so that both shorter production runs as well as semi-continuous and long-term production can be supported, to service a wider group of clients.

Hide Ad
Hide Ad

“This will involve reconfiguration of both operations and infrastructure over a period. The business development team will work closely with the site to maximise the potential revenue streams available.”

The accounts also show the firm increased its revenue from £5.1m in 2022 to £7.5m in 2023, but that it still ran an operating loss of £13.7m. This is down from a £22.4m operating loss in 2022.

Comment Guidelines

National World encourages reader discussion on our stories. User feedback, insights and back-and-forth exchanges add a rich layer of context to reporting. Please review our Community Guidelines before commenting.